-
Posted by
Two Blokes Jul 15 -
Filed in
Stock
-
1 view
- The combination study, conducted in the U.S., is designed to evaluate the safety, tolerability and preliminary efficacy at Day 29 of a single-dose of ultra-long-acting subcutaneously administered ASC47 (half-life up to 40 days) in combination with four doses of semaglutide (0.5 mg, once weekly) in 28 participants with obesity. - Initiated in May 2025, all 28 participants were enrolled in less than two months.
